Annex 2: Practice Thematic Summary of Learning Template Minimising the Harms of Poly-Pharmacy Practice identification and metrics Practice Name Practice W code GP Cluster Practice lead Date submitted (dd/mm/yyyy) __/__/____ Practice Summary of learning points Learning Specific learning points 3. Number of cases with these 4. Action prompted 5. Action prompted Point Themes identified in each case themes (expressed as fraction of at practice level at cluster level the medication reviews – e.g. 4/15) Need and Indication Open Questions (patient compliance)
Annex 2: Practice Thematic Summary of Learning Template Minimising the Harms of Poly-Pharmacy Practice identification and metrics Practice Name Practice W code GP Cluster Practice lead Date submitted (dd/mm/yyyy) __/__/____ Practice Summary of learning points Learning Point Themes Specific learning points identified in each case 3. Number of cases with these themes (expressed as fraction of the medication reviews – e.g. 4/15) 4. Action prompted at practice level 5. Action prompted at cluster level Need and Indication Open Questions (patient compliance)
5FinalPolypharmacyGuidance%202015.docx